RGNX

MKT CAP:$453M

REGENXBIO Inc.

Market Cap

$453M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$9.40-$4.17 (-30.73%)

Apr 23, 2026

Company Details

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are inte...

CEO

Curran Simpson

IPO Date

Sep 17, 2015

Website

www.regenxbio.com

Key Metrics TTM

Revenue

$170M

+104.5% YoY

Net Income

-$194M

EPS (Diluted)

-$3.76

Free Cash Flow

-$126M

Revenue / Share

$3.29

Gross Margin

52.9%

Operating Margin

-94.6%

Net Margin

-113.8%

FCF Margin

-74.1%

P/S

2.7x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 5, 2026

$170M+104.5%EPS -$3.76

Q4 2025

Mar 5, 2026

$30M+43.0%EPS -$1.30

Q3 2025

Nov 6, 2025

$30M+22.9%EPS -$1.20

Q2 2025

Aug 7, 2025

$21M-4.2%EPS -$1.38

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$22M	$7M	-$72M
Q2 22	$33M	$20M	-$63M
Q3 22	$27M	$13M	-$71M
Q4 22	$31M	$19M	-$58M
Q1 23	$19M	$15M	-$66M
Q2 23	$20M	$11M	-$73M
Q3 23	$29M	$17M	-$65M
Q4 23	$22M	$7M	-$64M
Q1 24	$16M	$7M	-$62M
Q2 24	$22M	$8M	-$56M
Q3 24	$24M	$12M	-$62M
Q4 24	$21M	$15M	-$51M
Q1 25	$89M	$86M	$12M
Q2 25	$21M	$12M	-$63M
Q3 25	$30M	-$32M	-$52M
Q4 25	$30M	$24M	-$58M

Valuation

Quarter	P/S	P/E
Q1 22	2.9x	13.6x
Q2 22	2.3x	12.3x
Q3 22	2.2x	14.2x
Q4 22	8.4x	—
Q1 23	7.7x	—
Q2 23	9.1x	—
Q3 23	7.1x	—
Q4 23	7.3x	—
Q1 24	12.6x	—
Q2 24	6.3x	—
Q3 24	6.3x	—
Q4 24	4.4x	—
Q1 25	2.3x	—
Q2 25	2.7x	—
Q3 25	3.1x	—
Q4 25	4.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$56M	-$67M
Q2 22	-$62M	-$71M
Q3 22	-$50M	-$56M
Q4 22	-$39M	-$45M
Q1 23	-$81M	-$86M
Q2 23	-$47M	-$50M
Q3 23	-$49M	-$51M
Q4 23	-$41M	-$42M
Q1 24	-$55M	-$56M
Q2 24	-$45M	-$46M
Q3 24	-$41M	-$41M
Q4 24	-$32M	-$33M
Q1 25	$34M	$33M
Q2 25	-$49M	-$50M
Q3 25	-$56M	-$56M
Q4 25	-$52M	-$53M

Capital Expenditures

Quarter	CapEx
Q1 22	$11M
Q2 22	$9M
Q3 22	$5M
Q4 22	$5M
Q1 23	$5M
Q2 23	$3M
Q3 23	$1M
Q4 23	$1M
Q1 24	$557.0K
Q2 24	$474.0K
Q3 24	$326.0K
Q4 24	$1M
Q1 25	$1M
Q2 25	$391.0K
Q3 25	$491.0K
Q4 25	$508.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+17.7%	+49.0%
Q2 22	+48.2%	+28.2%
Q3 22	-13.8%	+10.7%
Q4 22	-92.1%	+4.8%
Q1 23	-13.9%	-9.0%
Q2 23	-38.8%	-2.2%
Q3 23	+9.1%	-3.8%
Q4 23	-29.1%	-3.4%
Q1 24	-18.4%	-9.3%
Q2 24	+11.6%	-15.8%
Q3 24	-16.3%	-8.1%
Q4 24	-4.5%	-15.7%
Q1 25	+469.8%	-0.6%
Q2 25	-4.2%	+8.0%
Q3 25	+22.9%	-4.8%
Q4 25	+43.0%	+21.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$11M	48.6%
Q2 22	$10M	31.7%
Q3 22	$10M	38.6%
Q4 22	$9M	30.0%
Q1 23	$11M	58.6%
Q2 23	$11M	52.6%
Q3 23	$10M	35.3%
Q4 23	$8M	37.5%
Q1 24	$10M	61.5%
Q2 24	$9M	42.3%
Q3 24	$10M	40.8%
Q4 24	$10M	45.0%
Q1 25	$9M	9.6%
Q2 25	$9M	40.5%
Q3 25	$9M	30.3%
Q4 25	$8M	27.6%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$56M	$22M
Q2 22	$61M	$21M
Q3 22	$63M	$21M
Q4 22	$63M	$21M
Q1 23	$59M	$23M
Q2 23	$60M	$24M
Q3 23	$58M	$23M
Q4 23	$51M	$19M
Q1 24	$51M	$18M
Q2 24	$45M	$19M
Q3 24	$54M	$19M
Q4 24	$50M	$20M
Q1 25	$53M	$20M
Q2 25	$56M	$20M
Q3 25	$56M	$20M
Q4 25	$60M	$22M

Revenue Segments

Quarter	License And Service	License and Service	Service
Q1 22	$22M	—	—
Q2 22	$33M	—	—
Q3 22	$27M	—	—
Q4 22	—	$31M	—
Q1 23	$19M	—	—
Q2 23	—	$20M	—
Q3 23	—	$29M	—
Q1 24	—	$16M	—
Q2 24	—	$22M	—
Q3 24	—	$24M	—
Q4 24	—	$21M	—
Q1 25	—	$87M	$2M
Q2 25	—	$18M	$3M
Q3 25	—	$24M	$6M
Q4 25	—	$27M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$192M	$202M	$394M
Q2 22	$121M	$282M	$403M
Q3 22	$119M	$264M	$382M
Q4 22	$97M	$268M	$365M
Q1 23	$70M	$262M	$332M
Q2 23	$69M	$251M	$320M
Q3 23	$53M	$249M	$302M
Q4 23	$35M	$241M	$275M
Q1 24	$113M	$226M	$339M
Q2 24	$58M	$233M	$290M
Q3 24	$57M	$199M	$255M
Q4 24	$58M	$177M	$235M
Q1 25	$130M	$138M	$268M
Q2 25	$80M	$244M	$323M
Q3 25	$59M	$215M	$274M
Q4 25	$34M	$196M	$230M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	43M	-2.6%	+2.7%
Q2 22	43M	+0.4%	+1.4%
Q3 22	43M	+0.3%	+1.5%
Q4 22	43M	+0.1%	-1.8%
Q1 23	43M	+0.4%	+1.2%
Q2 23	44M	+0.2%	+1.0%
Q3 23	44M	+1.0%	+1.6%
Q4 23	44M	+0.1%	+1.6%
Q1 24	46M	+3.9%	+5.3%
Q2 24	51M	+10.6%	+16.2%
Q3 24	51M	+0.4%	+15.6%
Q4 24	51M	+0.1%	+15.6%
Q1 25	51M	+1.1%	+12.5%
Q2 25	51M	+0.1%	+1.7%
Q3 25	52M	+0.4%	+1.8%
Q4 25	52M	+0.1%	+1.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$59.7K	372
Q2 22	$87.8K	372
Q3 22	$71.3K	372
Q4 22	$78.2K	401
Q1 23	$47.7K	401
Q2 23	$49.8K	401
Q3 23	$72.1K	401
Q4 23	$64.6K	344
Q1 24	$45.4K	344
Q2 24	$64.8K	344
Q3 24	$70.3K	344
Q4 24	$60.1K	353
Q1 25	$252.2K	353
Q2 25	$60.5K	353
Q3 25	$84.2K	353
Q4 25	$152	200K

Revenue / Employee